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This trial aimed to assess the feasibility and tumour control of concurrent chemoradiotherapy or radiotherapy alone after docetaxel-
based induction chemotherapy in locally advanced non-small-cell lung cancer (NSCLC). Patients with stage IIIA/IIIB NSCLC received
two 21-day cycles of induction chemotherapy with docetaxel (85mgm
 2, day 1) plus cisplatin (40mgm
 2, days 1 and 2). Patients
without disease progression on day 43 were randomised to radiotherapy (2Gy for 5 daysweek
 1; total 60Gy) alone or with
docetaxel 20mgm
 2 once weekly every 6 weeks. Of 108 patients who received induction chemotherapy, 104 were evaluable for
response. After induction chemotherapy, the overall response rate (ORR) was 44%; 91 (88%) patients had no disease progression
and 89 were subsequently randomised to local treatment. After randomised therapy, the ORR was 53% (chemoradiotherapy 58%;
radiotherapy 48%). Median survival and time to progression were 14.9 and 7.8 months, respectively, for chemoradiotherapy and 14.0
and 7.5 months, respectively, for radiotherapy. The most common toxicities during induction chemotherapy and randomised therapy
were grades 3–4 neutropenia and grade 3 lymphocytopenia, respectively. Docetaxel–cisplatin induction therapy followed by
concurrent docetaxel and thoracic radiotherapy is a feasible treatment option, showing good clinical activity and tolerability, for locally
advanced NSCLC.
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Despite intensive investigation, the prognosis for patients with
lung cancer, up to 87% of whom have non-small-cell lung cancer
(NSCLC) at diagnosis, remains poor, with an estimated 5-year
survival rate of only 15.3% (Ries et al, 2005). The standard
treatment of locally advanced unresectable NSCLC is combined
chemotherapy and thoracic radiation, based on the results of
several randomised phase III trials (Schaake-Koning et al, 1992;
Dillman et al, 1996; Sause et al, 2000). Subsequent trials have
demonstrated the superiority of concurrent chemotherapy and
radiotherapy over a sequential approach (Furuse et al, 1999;
Curran et al, 2003; Zatloukal et al, 2004), although at the expense
of increased toxicity, in particular severe oesophageal toxicity.
Docetaxel – a new generation taxane – has shown efficacy with
acceptable toxicity in patients with NSCLC, both alone and in
combination with other chemotherapeutic agents (Davies et al,
2003). Results of a phase II study of cisplatin plus docetaxel as
induction chemotherapy before local treatment strongly support
the use of this approach for patients with locally advanced
resectable disease, with a complete response (CR) rate of 16% and
an impressive 33-month median survival (Betticher et al, 2003).
Docetaxel has been shown to be an effective radiosensitiser in
vitro (Creane et al, 1999; Pradier et al, 2001) and to act
synergistically in the presence of radiation in preclinical models
(Scagliotti and Turrisi, 2003). The feasibility of concurrent
treatment with single-agent docetaxel and radiotherapy for
unresectable advanced NSCLC was established in a series of small
phase I studies (Koukourakis et al, 1998; Mauer et al, 1998), and
response rates of up to 80% have been reported in phase II trials in
this setting (Kim and Khuri, 2002).
Based on these encouraging outcomes, this phase II study aimed
to evaluate the feasibility, efficacy and toxicity of induction
chemotherapy with docetaxel plus cisplatin, followed by radio-
therapy with or without weekly docetaxel, in patients with locally
advanced NSCLC.
PATIENTS AND METHODS
This prospective, randomised nonblind phase II study was
conducted in nine European centres. Inclusion criteria were: age
18–75 years; histologically or cytologically proven, locally
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sadvanced unresectable, NSCLC; uni- or bidimensionally measur-
able disease; no previous treatment for NSCLC; World Health
Organization (WHO) performance status p1; X12 weeks life
expectancy; weight loss p5% within 12 weeks of study entry;
adequate haematological, hepatic, renal and respiratory function.
Clinical biochemistry and haematology requirements were:
platelet count X100 10
9l
 1; absolute neutrophil count (ANC)
X2 10
9l
 1; haemoglobin level X10gdl
 1; serum creatinine and
bilirubin levels within the institution’s normal range; serum
transaminase levels p2.5 the upper normal limit (UNL); forced
expiratory volume in 1s and carbon monoxide diffusing capacity
X45% of the reference normal values at study entry.
Exclusion criteria included: pleural or pericardial effusion or
extensive vessel invasion; a diagnosis of small-cell lung cancer;
prior malignancies (except cured cervical carcinoma in situ or
nonmelanoma skin cancer or other curatively treated cancer with
no evidence of disease for X5 years); conditions precluding
medical follow-up and protocol compliance; history of hyper-
sensitivity reaction to polysorbate 80; peripheral neuropathy
(National Cancer Institute Common Toxicity Criteria (NCI-CTC)
grade X2); abnormal hepatic function (aspartate aminotransferase
and/or alanine aminotransferase 41.5 UNL associated with
alkaline phosphatase 42.5 UNL); serious comorbidities.
All patients provided written, informed consent. The study was
conducted in accordance with good clinical practice guidelines and
the Declaration of Helsinki.
Treatment plan
The treatment plan is summarised in Figure 1.
Induction chemotherapy Eligible patients received two 21-day
cycles of induction chemotherapy comprising docetaxel 85mgm
 2
(1-h intravenous (i.v.) infusion) on day 1 plus cisplatin 40mgm
 2
(30-min i.v. infusion) on days 1 and 2. Patients received
prophylactic oral dexamethasone 8mg bid on days  1 and 1 and
ondansetron 8mg i.v. infusion on days 1 and 2. Pre- and
postchemotherapy hydration was administered according to each
centre’s practice.
Dose modifications allowed due to toxicity were: docetaxel
75mgm
 2, cisplatin 40mgm
 2 2 for an ANC nadir of
o0.5 10
9l
 1 for 47 days, platelet nadir o25 10
9l
 1, febrile
neutropenia, or grades 3–4 skin toxicity or stomatitis; docetaxel
75mgm
 2, cisplatin 30mgm
 2 2 for grade 2 neurotoxicity,
grades 3–4 nonhaematological toxicity (except anaemia), or 41
toxicity/conflicting recommendations; docetaxel 85mgm
 2, cis-
platin 30mgm
 2 2 for nephrotoxicity grade p2 during the
previous cycle.
Patients were retreated on day 21 if: ANC was X1.5 10
9l
 1
and platelet count was X100 10
9l
 1; serum creatinine was grade
p1( p1.5 UNL) and creatinine clearance was X60mlmin
 1;
nonhaematological toxicities (except alopecia, anaemia and fluid
retention) had resolved to grade p1. If toxicity grade 41 persisted
at day 21, treatment was delayed for up to 2 weeks. Patients with
grade 3 neurotoxicity were taken off the study medication. Serum
transaminase and alkaline phosphatase levels p5.0–42.5 UNL
on day 21 required a reduction in docetaxel dose to 75mgm
 2 for
cycle 2; transaminase and alkaline phosphatase levels 45 UNL
or total bilirubin above the UNL required a treatment delay for
up to 2 weeks. Patients discontinued treatment if liver toxicity
persisted after dose reduction. Docetaxel was withheld in patients
with moderate or severe hypersensitivity reaction until recovery
from symptoms; dexamethasone 10mg and/or diphenhydramine
50mg infusion was recommended for moderate hypersensitivity,
and epinephrine was given as needed for severe hypersensitivity.
Antiemetic and antiallergic drugs were administered as needed.
Prophylactic use of granulocyte- or granulocyte macrophage-
colony-stimulating factor and other growth factors was not allowed
during the first treatment cycle, although prophylactic dexametha-
sone 8mg was given on the day before and the day of docetaxel
administration.
Local treatment Tumours were reevaluated on day 43 by chest
X-ray and thoracic computed tomography (CT) scan, and patients
with progressive disease (PD) were withdrawn from the study. The
remaining patients were randomised to thoracic radiotherapy
(2Gy for 5 days each week to a total of 60Gy using equipment that
delivered megavoltage photons X6MeV) either alone or with
docetaxel 20mgm
 2 (30-min infusion) once-weekly for 6 weeks.
Radiation was administered 2–4h after completing the docetaxel
infusion (based on the European Organisation for the Research
and Treatment of Cancer (EORTC) Radiotherapy Group and
International Commission on Radiation Units and Measurements
(ICRU) 50 recommendations (International Commission on
Radiation Units and Measurements, 1993), computed tomography
planning was mandatory. The radiation dose was administered to a
planning target volume that included the radiologically visible
primary tumour plus 1.5–2cm margins and involved lymph nodes
(including mediastinal lymph nodes 41.5cm in their smallest
diameter) plus 1–1.5cm margins plus elective irradiation of the
mediastinal lymph node regions 2–8 and the ipsilateral hilar
lymph nodes. The clinical tumour volume for the primary tumour
was either the pre- or postchemotherapy tumour volume,
according to the single investigator’s opinion. It was recommended
that o30% of the total lung volume should receive 425Gy and
o50% of the total lung volume should receive 420Gy (from
November 2000, all radiotherapist investigators recommended a
V20 p40%, though consensus was reached that the protocol would
not be amended in this respect). The heart could tolerate the
tumour radiation dose if applied to o30% of its volume but could
tolerate o50% of the tumour dose if applied to 450% of its
volume. The spinal cord received p75% of the tumour dose and
p15cm of the oesophagus was included in the high-dose volume.
The protocol for the radiotherapy procedure was amended after
the start of enrolment (7 April 2000) in order to reduce the
magnitude of the irradiated field and the potential toxicity of the
treatment, following four suspected cases of treatment-related
pneumonitis in the first 36 patients enrolled in the study (although
in three cases the serious adverse event was later concluded to be
pneumonia rather than pneumonitis). The clinical tumour volume
Induction chemotherapy: docetaxel 85 mg m
−2 day 1+
cisplatin 40 mg m
−2 days 1 and 2 every 3 weeks×2 cycles
Tumour re-evaluation on day 43
(chest X-ray+thoracic CT scan)
PR, CR, NC PD
Withdrawal from study
Randomisation
Chemoradiotherapy Radiotherapy alone
Radiotherapy (2 Gy on 5 days/week to 60 Gy)
+docetaxel 20 mg m
−2/week for 6 weeks
2 Gy on 5 days/week to 60 Gy
Figure 1 Treatment plan. CR¼complete response; NC¼no change;
PD¼progressive disease; PR¼partial response.
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the prechemotherapy or the postchemotherapy tumour volume
according to the single investigator’s opinion; the defined
inclusion of the mediastinal lymph nodes, regions 2–8 and the
hilar lymph nodes coded as 10 in the clinical tumour volume for
the adjacent nodal draining area; and elective irradiation of the
mediastinal lymph node regions 2–8 and the ipsilateral hilar
lymph nodes was removed. To assure quality control of radio-
therapy, planning information, simulator films and dose distribu-
tions, including dose volume histograms, and a copy of the
treatment prescription were made available for central review.
No dose modifications were planned for local treatment. In the
case of toxicity, docetaxel infusion was interrupted until resolution
to grade p1, up to a maximum cumulative delay of 10 days.
Patients were withdrawn if the schedule was interrupted for 47
consecutive days due to intercurrent illness.
Patient evaluation
All patients underwent a full physical examination (including
determination of WHO performance status, weight loss, vital signs
and lung function) and clinical biochemistry tests at baseline, 3-
weekly during induction chemotherapy, and again before and after
local treatment. Assessments for haematology, hepatic function
and toxicity were conducted at baseline, 3-weekly during induction
chemotherapy (weekly for complete blood count haemoglobin,
lymphocytes (with white blood cell differentials) and platelets),
and weekly throughout local treatment (every 2 days in case of
grade 4 or febrile neutropenia). Anteroposterior/lateral chest X-ray
and thoracic CT scan (including upper abdomen scan to assess
liver and adrenal gland status) were performed p2 weeks and p4
weeks, respectively, before starting induction chemotherapy;
thoracic CT scan was repeated p1 week after finishing induction
chemotherapy and p12 weeks after starting local treatment.
Brain CT and bone scans were performed if clinically indicated.
Nonmeasurable lesions were evaluated by appropriate clinical and/
or radiological examination. Tissue or cytologic diagnosis was
made using biopsy/brushing or bronchial aspirate obtained during
fibreoptic bronchoscopy or, alternatively, transthoracic aspiration
biopsy of the primary tumour. After withdrawal or completion of
study treatment, patients were followed up every 3 months until
PD, for a maximum of 1 year from the date of last local treatment
of the last patient enrolled in the study. Any treatment-related side
effects were followed until resolution.
Tumour response was assessed according to WHO criteria
(WHO, 1979) (except that response to induction therapy did not
require confirmation 4 weeks later). A CR was defined as the
disappearance of all measurable lesions for X4 weeks, a partial
response (PR) as a decrease of X50% of the sum of the products of
the greatest perpendicular lesion diameters for X4 weeks with no
evidence of new lesions, and no change (NC) as a o50% decrease
or o25% increase in the products of the greatest perpendicular
lesion diameters with no evidence of new lesions for X4 weeks.
Progressive disease was defined as an increase in lesion diameter
products of X25% or the detection of new lesions. Time to
progression (TTP) was defined as the time from the start of
induction therapy until first progression or death due to PD.
Survival was determined from the start of induction therapy to
death from any cause.
Toxicity was assessed using NCI-CTC. Toxicities not reported
in the NCI-CTC scale were graded as mild, moderate, severe or
life threatening, according to MedDRA (Medical Dictionary for
Regulatory Activities) 6.1. An adverse event was reported as
serious if it: was fatal or life threatening; required or prolonged
hospitalisation; resulted in persistent or significant disability or
incapacity; was a congenital anomaly or birth defect; was an
important medical event. All patients were evaluable for toxicity
from the time of their first dose of study drug.
Efficacy was evaluated in all patients who were allocated to
randomised therapy after induction treatment, with patients
stratified according to centre and disease stage. The primary
objective was overall response rate (ORR) at study end (i.e. 12
weeks from randomisation) for the intent-to-treat (ITT) popula-
tion. The main secondary efficacy analyses were ORR at week 12
for the population evaluable for response to local treatment
(defined as all responders to induction therapy who had received
X3 weekly administrations of docetaxel plus 6 weeks of radiation
(chemoradiotherapy arm) or X6 weeks of radiation (radiotherapy
only arm), unless progression occurred in which case the outcome
was described as early PD), and TTP and survival in the ITT
population were determined by Kaplan–Meier analysis.
The minimum sample size was 37 evaluable patients based on
a single-stage Fleming design. Combined treatment would be
considered insufficiently or sufficiently promising for further
study if the ORRs were p30 and X53%, respectively (type I error
of 5% and type II error of 10%). Assuming that 10% of patients
would be nonevaluable and approximately 20% would not be
randomised, it was calculated that 105 patients should be enrolled.
RESULTS
Patients and treatment administration
Overall, 108 patients were enrolled between December 1999 and
October 2001. Table 1 shows the baseline patient and tumour
characteristics. Most participants had stage IIIB disease. All
enrolled patients started at least one cycle of induction
chemotherapy and were included in the safety population. Of
these, 104 patients were evaluable for response to induction
chemotherapy: the ORR was 46/104 (44%, all PRs), with NC in 45
patients (43%). Thus, 91 patients (88%) did not have PD (Table 2).
Eighty-nine patients were subsequently randomised to local
treatment (ITT population). Reasons for treatment discontinuation
among the remaining 19 patients were: PD (n¼10), protocol
deviation (n¼1), adverse event (n¼2), death (n¼3) and other
Table 1 Patient characteristics at baseline (before induction chemo-
therapy)
Parameter Value (n¼108)
Median age, years (range) 59 (38–75)
Gender, n (%)
Male 84 (78)
Female 24 (22)
WHO performance status, n (%)
0 21 (19)
1 87 (81)
Histology, n (%)
Adenocarcinoma 36 (33)
Large cell carcinoma 7 (6)
Squamous cell carcinoma 47 (44)
Other 18 (17)
Disease stage, n (%)
IIIA 27 (25)
IIIB 81 (75)
Site of disease, n (%)
Lung 106 (98)
Lymph nodes 96 (89)
Mediastinum 1 (1)
WHO¼World Health Organization.
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s(n¼3: investigator decision, metastasis, massive decay of lesions (a
contraindication for radiotherapy owing to the high risk of developing
life-threatening pulmonary haemorrhage) (one patient each)).
The 89 patients comprising the ITT population were randomised
to receive chemoradiotherapy (n¼43) or radiotherapy alone
(n¼46). Of these, 22 had stage IIIA and 67 had stage IIIB disease.
Patient characteristics were well balanced between the chemo-
radiotherapy and radiotherapy-only groups: stage IIIB disease in
74 and 76% of patients, respectively; WHO performance status of
one in 79 and 78%, respectively; and squamous cell histology in 42
and 46%, respectively. Full response data after randomisation were
available for all 89 patients; however, 15 patients were considered
nonevaluable (nine in the chemoradiotherapy arm and six in the
radiotherapy alone arm). Thus, 74 patients were considered
evaluable for response to local treatment (per protocol (PP)
population); the main reasons for nonevaluability were receiving
o6 weeks of local treatment and lesion measured using a different
method than at baseline.
The median cumulative doses of docetaxel and cisplatin
administered during induction therapy were 170mgm
 2 (range:
84–180mgm
 2) and 160mgm
 2 (53–172mgm
 2), respectively
(n¼108). The median relative dose intensity was 98% for both
agents (range: 53–106% for docetaxel and 53–108% for cisplatin).
No chemotherapy administrations were delayed during the
induction period. Five patients required docetaxel dose reduction
during induction chemotherapy because of serious adverse events
(SAEs): fever without infection (n¼1), grades 3–4 infection with
neutropenia (n¼3), and grade 3 dyspnoea and vomiting (n¼1).
During randomised therapy, the median cumulative docetaxel
dose administered in the chemoradiotherapy arm was 120mgm
 2
(range: 20–132mgm
 2; n¼41) and the median relative dose
intensity was 95% (44–117%). Only one patient required docetaxel
dose reduction during local treatment (from 20 to 10mgm
 2 for
five cycles because of grade 1 oesophagitis). Chemotherapy was
delayed in five patients for up to 1 week in only 6/411 cycles
administered during local treatment; reasons were: dysphagia
(three cycles in two patients); stomatitis (one cycle); no reason
given (two cycles). Delivery of radiotherapy closely followed the
planned dosage schedule in both treatment arms.
Response to local treatment
In the ITT population, the ORR to combined induction
chemotherapy and local treatment was 53% (47/89 patients; three
CR, 44 PR; PP: 44/74 (59%; three CR and 41 PR)); 58% (two CR
and 23 PR) after chemoradiotherapy and 48% (one CR and 21 PR)
after radiotherapy alone (Table 2). The proportion of patients with
no PD was 65% (two CR, 23 PR and three NC) in the
chemoradiotherapy arm and 57% (one CR, 21 PR, four NC) in
the radiotherapy arm. In the PP population, the ORR was 65% (two
CR and 20 PR) after chemoradiotherapy and 55% (one CR and 21
PR) after radiotherapy; the proportion of patients with no PD was
71% (two CR, 20 PR and two NC) and 65% (one CR, 21 PR and
four NC), respectively.
In stage IIIA patients, the ORR for chemoradiotherapy and
radiotherapy was 64 and 45%, respectively, in the ITT analysis
(Table 2) and 86 and 50%, respectively, in the PP analysis. In stage
IIIB patients, the ORR to chemoradiotherapy and radiotherapy was
56 and 49%, respectively, in the ITT analysis and 59 and 57%,
respectively, in the PP analysis. Two CR to chemoradiotherapy
were achieved, irrespective of staging. One CR was seen with
radiotherapy alone in a stage IIIB patient.
Overall, 23 and 31 patients in the chemoradiotherapy and
radiotherapy alone arms, respectively, had a tumour relapse
during the study (excluding the follow-up period). In the
chemoradiotherapy arm, 13 patients had a relapse into the lung
or mediastinum (three outside the field of irradiation) and nine
relapsed outside this area; information on relapse location was
missing for one patient. In the radiotherapy alone arm, 18 patients
had a relapse into the lung or mediastinum (four outside the field
of irradiation) and 10 relapsed outside this area; information on
relapse location was missing for three patients.
Survival The overall median survival across the ITT population
was 14.6 months (95% confidence interval (CI): 11.20–16.20
months). The median survival was similar in the chemoradio-
therapy and radiotherapy alone arms: 14.9 months (95% CI: 10.02–
22.21 months) and 14.0 months (95% CI: 11.10–15.67 months),
respectively (Figure 2A). The 1-year survival rates were also
similar: 55.8% (95% CI: 39.88–70.92%) and 58.7% (95% CI: 43.23–
73.00%) in the chemoradiotherapy and radiotherapy arms,
respectively.
In stage IIIA patients, the 1-year survival rate was 63.6% with
chemoradiotherapy and 72.7% with radiotherapy.
The median TTP was 7.6 months (95% CI: 7.03–9.43 months):
7.8 months (95% CI: 7.03–10.71 months) with chemoradiotherapy
and 7.5 months (95% CI: 6.83–9.43 months) with radiotherapy
alone (Figure 2B).
Safety and toxicity
Overall, neutropenia and leucopenia were the most common NCI–
CTC grades 3–4 haematological adverse events during induction
chemotherapy, occurring in 420% of patients (Table 3). Lym-
phocytopenia and febrile neutropenia were noted much less
frequently (febrile neutropenia of any grade affected only 6% of
Table 2 Overall response at the end of induction chemotherapy and at study end (ITT population)
After local treatment
After induction
chemotherapy
ITT
population
Chemoradiotherapy Radiotherapy alone
Response, n (%) Total (n¼104)
Total
(n¼89)
Stage IIIA
(n¼11)
Stage IIIB
(n¼32)
Total
(n¼43)
Stage IIIA
(n¼11)
Stage IIIB
(n¼35)
Total
(n¼46)
Overall response (%) 46 (44) 47 (53) 7 (64) 18 (56) 25 (58) 5 (45) 17 (49) 22 (48)
95% Confidence interval — — 31–89 38–74 42–73 17–77 31–66 33–63
Complete response 0 3 (3) 1 (9) 1 (3) 2 (5) 0 1 (3) 1 (2)
Partial response 46 (44) 44 (49) 6 (55) 17 (53) 23 (53) 5 (45) 16 (46) 21 (46)
No change 45 (43) 7 (8) 1 (9) 2 (6) 3 (7) 0 4 (11) 4 (9)
Progressive disease 9 (9) 19 (21) 2 (18) 5 (16) 7 (16) 6 (55) 6 (17) 12 (26)
Early progression
a 4 (4) 8 (9) 0 4 (13) 4 (9) 0 4 (11) 4 (9)
Nonevaluable — 8 (9) 1 (9) 3 (9) 4 (9) 0 4 (11) 4 (9)
aProgression before the first assessment of the response, that is before completion of two cycles of induction chemotherapy (6 weeks) or before completion of local treatment
(3 weekly administrations of docetaxel plus 6 weeks of radiation (chemoradiotherapy arm) or at least 6 weeks of radiation (radiotherapy only arm)).
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spatients). Alopecia was the most frequent treatment-related
nonhaematological toxicity (60 patients (56%), all grades).
Grade 3 lymphocytopenia was the most commonly reported
toxicity during local treatment: 80% for chemoradiotherapy and
20% for radiotherapy alone. However, grades 3–4 infection and
related adverse events occurred infrequently (e.g. infection without
neutropenia: 7 and 0%, cough: 2 and 0%, dyspnoea: 5 and 7% for
chemoradiotherapy and radiotherapy, respectively), showing no
evidence that lymphocytopenia was associated with a higher
infection risk. Alopecia, oesophagitis and fatigue (mostly grades
1–2) were the most common nonhaematological toxicities during
local treatment, each affecting around 50% or more of patients in
both groups (all grades). Oesophagitis, the most frequently
reported grade 3 nonhaematological toxicity, only affected patients
receiving chemoradiotherapy (17%) (Table 3). There were only
three grade 4 events during local treatment: infection without
neutropenia (one chemoradiotherapy patient) and dyspnoea (one
patient per arm).
The most common treatment-related SAE of any grade reported
during induction therapy was febrile neutropenia (7/108; 6%).
Table 4 shows the treatment-related SAEs affecting X5% of
patients during the local treatment period and follow-up phase.
Dysphagia/oesophagitis was more common with chemoradiation
than radiotherapy alone; other treatment-related SAEs were
generally similar between the arms.
In total, three patients (two chemoradiotherapy patients and one
radiotherapy patient) had a SAE of pneumonitis during the local
treatment period or follow-up phase: two cases were fatal (one per
arm) and considered related to therapy; both occurred 430 days
after the last administration of study treatment.
Overall, 11/108 patients (10%) discontinued study treatment due
to toxicity: four during induction chemotherapy (one patient each
due to grade 4 dyspnoea, fever without infection, fatal lung
haemorrhage, sudden death possibly caused by myocardial
infarction or stroke); three with chemoradiotherapy (infection
without neutropenia (two patients), grade 3 dysphagia/oesophagi-
tis (one patient)); and four with radiotherapy alone (all because of
infection without neutropenia).
Eleven patients died within 30 days of the last infusion: four
chemoradiotherapy patients; one radiotherapy alone patient; six
nonrandomised patients. Six patients (four who received induction
chemotherapy only and two in the chemoradiotherapy arm) had
malignant disease recorded as the cause of death. None of the five
deaths following an adverse event was considered related to study
treatment; causes of death were heart failure (one chemo-
radiotherapy patient), sudden death of unknown cause (one
chemoradiotherapy patient), grade 4 pneumonia without neutro-
penia (one radiotherapy-only patient (this event was initially
reported as radiation-related but was subsequently revised as
pneumonia unrelated to study treatment)), lung haemorrhage
(n¼1, induction chemotherapy only), and sudden death caused by
possible stroke or myocardial infarction (n¼1, induction chemo-
therapy only).
Sixty-four patients died 430 days after the last infusion (20
chemoradiotherapy patients, 32 radiotherapy-alone patients and
12 nonrandomised patients); most were due to PD (60 patients;
94%). Of the four resulting from SAEs, one death (radiotherapy
arm) resulting from radiation pneumonitis was initially considered
by the investigator to be unrelated to study treatment, but this
was revised subsequently to pneumonitis probably related to
study radiotherapy. A second death due to pneumonitis was also
considered related to study treatment and occurred in a patient
who received chemoradiotherapy and developed diffuse alveolar
damage. The other two adverse-event related-deaths were con-
sidered unrelated to study treatment and occurred as a result of
myocardial infarction (one chemoradiotherapy patient) and
respiratory insufficiency (one radiotherapy alone patient).
DISCUSSION
In this study, docetaxel and cisplatin (a combination noted for its
activity relative to other platinum-based doublets as first-line
therapy in advanced NSCLC (Fossella et al, 2003)) resulted in no
PD (i.e. achieved PR or NC) in 88% of patients. Following
induction chemotherapy, outcomes with chemoradiotherapy and
radiotherapy alone were similar, although there was a trend in
favour of the chemoradiotherapy group. There were two (5%) CR
with chemoradiotherapy and one (2%) with radiotherapy alone;
the PR rate was also higher in patients treated with chemo-
radiotherapy vs radiotherapy alone (53 vs 46%). As expected,
stage IIIA patients gained particular benefit from concomitant
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Figure 2 Kaplan–Meier curve of estimated (A) survival and (B) time to
disease progression in patients receiving radiotherapy plus docetaxel
(n¼43) or radiotherapy alone (n¼46) following induction chemotherapy.
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schemoradiotherapy, achieving an ORR almost 20% higher than
those treated with radiotherapy alone. Notably, the ORR of 58%
achieved with the induction chemotherapy plus chemoradiation
regimen met the criterion (ORR X53%) needed to reject the
hypothesis that this approach is insufficiently active to justify
further investigation. Median survival times in the current study
were also similar between the two arms (14.0 months with
induction chemotherapy before radiotherapy alone and 14.9
months with induction chemotherapy before concurrent chemor-
adiation; the median survival time of 14.0 months with the
sequential chemotherapy then radiotherapy-alone approach was
within the range of 13.3–14.6 months seen with a sequential
approach in previous phase III trials (Furuse et al, 1999; Curran
et al, 2003; Fournel et al, 2005).
Overall, the study therapy was well tolerated. Severe febrile
neutropenia was noted in a small proportion of patients in the
induction phase only. No febrile neutropenia was seen after
randomisation in either treatment group. Lymphocytopenia, a
predicted adverse event with local radiotherapy and commonly
observed when taxanes are administered with radiotherapy
(Reckzeh et al, 1996; Robert et al, 1999), affected most patients
who received chemoradiotherapy; however, no grade 4 cases were
reported and no increase in vital or opportunistic infections was
observed. Notably, our study demonstrated good overall tolerance
of the chemoradiotherapy schedule used, with few toxicities
reported with an incidence X5%. The incidence of grade 3
oesophagitis was 17% (no grade 4), which was not over the
expected rate (Mauer et al, 1998). Pneumonitis was reported as the
principal toxicity in a recent study of concurrent two-dimensional
radiotherapy (60–66Gy) plus weekly docetaxel 20mgm
 2 and was
considered by the authors to have adversely affected survival
(Onishi et al, 2003). In the current study, treatment-related
pneumonitis occurred to a similar extent with radiotherapy alone
and chemoradiotherapy (one and two patients, respectively), and
was fatal in one patient per arm.
The two 21-day cycles of induction chemotherapy in our study
produced an ORR of 44%, which is similar to the 45% ORR seen in
a phase II study of three cycles of the same induction
chemotherapy in patients with stage IIIA (pN2) NSCLC (Manegold
et al, 2004), although greater toxicity was seen in the latter study.
This induction regimen produced a greater ORR (66%) in patients
with resectable stage III (pN2) NSCLC (Betticher et al, 2003), likely
due to the relatively low volume of disease in these patients.
Also similar to our findings, a preliminary analysis of a phase III
randomised study, in which 219 nonprogressing patients with
unresectable stage III NSCLC received two cycles of induction
paclitaxel and carboplatin followed by radiotherapy with or
without weekly paclitaxel, found a lower progression rate after
chemoradiotherapy (48/109; 48%) than after radiotherapy alone
(28/89; 32%) (Huber et al, 2003).
Table 3 Haematological and nonhaematological toxicity: NCI-CTC grades 3–4 adverse events
a noted in X5% of patients in any treatment group
Randomised therapy
Toxicity NCI-CTC grade Induction chemotherapy (n¼108) Chemoradiotherapy
b (n¼41)
c Radiotherapy alone (n¼46)
Haematological, n (%)
Leucopenia 28 (26) — —
Lymphocytopenia 5 (5)
d 33 (80)
d 9 (20)
d
Neutropenia 50 (46) — 1 (2)
d
Febrile neutropenia 7 (6)
e ——
Nonhaematological
f, n (%)
Infection (without neutropenia) — 3 (7) —
Vomiting 5 (5)
d ——
Oesophagitis/dysphagia — 7 (17)
d —
Fatigue 3 (3)
d 5 (12)
d 2 (4)
Dyspnoea 1 (1) 2 (5) 3 (7)
NCI-CTC¼National Cancer Institute Common Toxicity Criteria (version 2.0).
aSerious adverse events are reported separately.
bLocal treatment period includes the 30 days
after the last infusion for nonhaematological toxicities and the 7 days after the last infusion for haematological toxicities.
cTwo patients were excluded owing to being randomised
to local treatment but not receiving their randomised therapy.
dAll grade 3.
eIncludes all grades of febrile neutropenia.
fAlopecia graded in error as grade 3 was reported in 11
(10%) patients during induction chemotherapy, and in five (12%) and two (4%) patients in the chemoradiotherapy and radiotherapy groups, respectively, during randomised
therapy. According to NCI-CTC classification, grades 3 and 4 cannot be applied to alopecia.
Table 4 Treatment-related serious adverse events affecting X5% of patients during the local treatment period
a and follow-up phase
Number of patients (%)
Toxicity NCI-CTC grade Induction chemotherapy only (n¼21) Chemoradiotherapy (n¼41)
b Radiotherapy alone (n¼46)
Oesophagitis/dysphagia — 7 (17) —
Infection without neutropenia grade 4 — 4 (10) 2 (4)
Fever without infection or neutropenia grade 4 1 (5) 3 (7) 4 (9)
Pneumonitis — 2 (5) —
Dyspnoea — 2 (5) 2 (4)
Infection with neutropenia grade 4 1 (5) 2 (5) 1 (2)
Anaemia 1 (5) — —
Cardiac dysrhythmia 1 (5) — —
Reduced performance status 1 (5) — —
Vomiting 1 (5) — —
aLocal treatment period includes the 30 days after the last infusion for nonhaematological toxicities and the 7 days after the last infusion for haematological toxicities.
bTwo
patients were excluded owing to being randomised to local treatment but not receiving their randomised therapy.
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sConsolidation docetaxel after concurrent chemoradiotherapy
has been investigated as an alternative sequencing approach to
induction chemotherapy. In a phase II study, stage IIIB patients
received consolidation docetaxel after concurrent cisplatin, etopo-
side and radiotherapy (Gandara et al, 2003). Median progression-
free and overall survival times were 16 and 26 months,
respectively. The regimen was generally well tolerated, although
grade 4 neutropenia was reported in 57% of patients receiving
consolidation docetaxel, and was most common when the
docetaxel dose was escalated to 100mgm
 2. It remains to be
determined whether induction chemotherapy before concurrent
chemoradiotherapy or concurrent chemoradiotherapy followed by
consolidation chemotherapy is the most effective sequence, but the
latter approach has thus far produced the longest survival times.
It is important to note that some patients with locally advanced
NSCLC do not meet the tumour volume requirements when planning
radiotherapy at baseline and thus cannot be selected in advance for
chemoradiotherapy protocols. Induction chemotherapy might poten-
tially rescue some patients presenting with bulky disease if a policy of
encompassing the postchemotherapy tumour volume is adopted.
In conclusion, two cycles of docetaxel–cisplatin induction
therapy followed by concurrent docetaxel and thoracic radio-
therapy appears to represent a feasible treatment option for
patients with locally advanced NSCLC. However, the results of the
current study were not sufficiently compelling to design a phase III
study of this approach. Instead, in a phase II study in patients
with unresectable stage III NSCLC, we are currently evaluating
the benefit of adding weekly cisplatin to weekly docetaxel
plus concurrent radiotherapy after cisplatin–docetaxel induction
therapy in one arm and before cisplatin–docetaxel consolidation
chemotherapy in the second arm.
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